Apolipoprotein E is a multifunctional protein synthesized by hepatocytes and macrophages.
Introduction
Apolipoprotein E (apoE) is a multifunctional protein produced largely by the liver and mononuclear phagocytes (1) . Although its physiologic role is uncertain, macrophage-derived apoE can inhibit progression of atherogenesis. Expression of macrophage apoE in apoE deficient mice using bone marrow transplantation reduced plasma cholesterol levels and slowed progression of atherosclerosis (2, 3) . Tissue-specific transgenic expression reduced atherosclerosis independent of plasma cholesterol levels (4) . Transplantation of apoE deficient bone marrow in wild-type mice increased atherosclerosis (5) , consistent with a role of macrophage-derived apoE in inhibiting progression of atherosclerosis.
Liver-derived apoE is the major source of plasma apoE and has an important physiologic role in regulating lipoprotein metabolism (1) . However, the potential role of liver-derived apoE in atherogenesis independent of its role in lipoprotein metabolism is uncertain. Expression of apoE in the liver of apoE deficient mice using an adenoviral vector slowed the progression of atherosclerosis (6) .
We demonstrated that adenoviral-mediated hepatic expression of apoE in apoE deficient mice resulted in marked regression of both early and advanced atherosclerotic lesions (7) , an observation confirmed subsequently by another group (8) . However, in all of these experiments, hepatic expression of apoE in apoE-deficient mice markedly reduced plasma cholesterol levels, making it impossible to assess the direct effect of liver-derived apoE on atherosclerosis.
A previous study showed that repeated injection of purified apoE to Watanabe Heritable Hyperlipidemic (WHHL) rabbits lacking functional LDL receptors resulted in reduced progression of atherosclerosis without lowering plasma cholesterol levels (9) . We subsequently demonstrated that hepatic expression of apoE in LDLR receptor-deficient mice fed a western-type diet did not reduce plasma cholesterol levels but nevertheless slowed the progression of early fatty-streak atherosclerotic lesions (10) . Expression of apoE by the adrenals at plasma levels below the threshhold for reducing plasma cholesterol levels reduced atherosclerosis in apoE deficient mice (11) . However, regression of atherosclerosis by apoE derived from any source in the absence of cholesterol reduction has never been demonstrated. In the current study, we extended previous observations by testing the hypothesis that apoE expression would induce regression of preexisting advanced atherosclerotic lesions in the absence of significant reduction in plasma cholesterol.
The mechanisms by which apoE directly inhibits atherosclerosis are poorly understood. One of the key factors that plays a causative role in development and progression of atherosclerosis is oxidative stress (12) . Oxidative stress in the artery wall contributes to the inflammatory nature of atherosclerotic lesions (12, 13) and could potentially contribute to plaque rupture (14) . Products of lipoprotein oxidation are present in vessel wall and have pro-inflammatory effects that could promote atherogenesis (15) . ApoE-deficient mice exhibit evidence of markedly increased lipoprotein oxidation as assessed by autoantibodies to oxidized lipoproteins (15) . ApoE has been shown in vitro to have antioxidant (16) and anti-inflammatory (17) properties. In this study, we investigated effects of apoE expression on in vivo oxidative stress by quantitating isoprostanes in multiple tissues. Isoprostanes are stable prostaglandin isomers generated during free radical-mediated lipid peroxidation and have been shown to be reliable markers of lipid peroxidation and oxidative stress generation in vivo (18) .
We previously reported that urine, plasma, and arterial iPF 2 α-VI levels are markedly increased in apoE deficient mice and are suppressed by the administration of vitamin E accompanied by reduction in atherosclerosis (19) . Therefore, we also tested the hypothesis that hepatic expression of apoE would reduce oxidant stress in LDLR deficient mice as assessed by quantitation of isoprostanes in urine, plasma, and aorta.
Experimental Procedures

Animal experimental protocol
Recombinant second-generation adenovirus encoding the human apoE3 and the control empty adenovirus (Adnull) were constructed as described previously (7, 20) . A total of 27 LDLR-/-mice (back-crossed 10 times to C57BL/6 mice) obtained from Jackson Labs were fed a western-type diet (normal chow supplemented with 0.15% cholesterol and 20% butter fat) for a total of 14 weeks prior to baseline analysis or administration of vector. Blood was drawn one week prior to vector administration, plasma cholesterol was quantified, and mice were divided into three groups with mean cholesterol levels that were not significantly different. One day prior to vector adminstration, one group of mice (n=9) were killed for analysis of atherosclerosis (baseline group). Remaining mice were injected intravenously with either AdhapoE3 (n=9) or control Adnull virus (n=9) at a dose of 1.0 X 10 11 particles (approximately 6.0 X 10 9 pfu per gram body weight). The western-type diet was continued after vector administration. Blood samples from mice were obtained by retro-orbital plexus prior to injection and 7, 14, 21, 28, and 42 days after injection. Blood samples were collected into tubes containing 2 nM EDTA, 0.2% NaN3, 0.77% gentamycin and were centrifuged to obtained plasma, which was stored at - 
Lipid and Lipoprotein Analyses
Plasma cholesterol and triglyceride levels were measured enzymatically on a Cobas Fara II (Roche Diagnostic Systems Inc., NJ) using Sigma reagents. Plasma apoE levels were measured using an immunoturbidometric assay (Sigma, St. Louis, MO). Plasma samples (200 µL pooled from 9 mice each of Adnulll and AdhapoE3 group) were analyzed by Fast Protein Liquid Chromatography (FPLC) gel filtration (Pharmacia LKB Biotechnology, Uppsala, Sweden) on two Superose 6 columns as previously described (20) . The cholesterol concentrations in the FPLC fractions were determined using an enzymatic assay (Wako Pure Chemical Industries Ltd., Osaka, Japan). 
Analysis of atherosclerosis
The extent of atherosclerosis in the aorta and in aortic cross sections was analyzed as described previously (7, 19, 21, 22) . Mice were killed by carbon dioxide inhalation and the aorta was immediately perfused in situ with ice-cold PBS for 10 min via the left ventricle. The heart and aorta were removed en bloc and the heart was severed from the aorta just above the aortic root. The apical half of the heart was cut off in a plane perpendicular to the aortic root. The upper half of the heart containing the aortic root was immediately embedded in OCT and frozen at -80 O C. The remainder of the aorta was cleaned free of adventitial fat and tissue, opened longitudinally, stained with Sudan IV, and pinned out as described (7, 19, 21, 22) . The extent of atherosclerosis in aortas was quantified by capturing images of aorta with a Dage-MTI 3CCD three chip color camera (Dage-MTI Inc., Michigan City, IN) connected to a Leica MZ 12 dissection microscope. The captured 24-bit digitized color images were analyzed and the lesion areas covering aortas were determined using Image Pro Plus image analysis software (Media Cybernetics, Silver Spring, MD). The acquisition of aortic images and the analysis of lesion areas were both performed in a blinded fashion.
Atherosclerosis was also quantified in the aortic root cross-sections from the fresh-frozen OCT embedded hearts (7, 22) . Serial 8 µM sections of the aortic root were cut and mounted on slides, then fixed in acetone, rehydrated in PBS containing 0.02% NaN3 and blocked with 1%BSA in PBS/NaN3.
For detection of macrophages, sections were immunostained with monoclonal rat anti-murine MAC-1 antibody, monoclonal hamster anti-CD18, and monoclonal hamster anti-CD11c.For detection of an extracellular matrix protein, monoclonal hamster laminin antibody was used as a primary antibody, followed by incubation with mouse anti-rat or goat anti-hamster IgG in the presence of 200 µg/mL normal mouse IgG. Antibody reactivity was detected using HRP-conjugated biotin-streptavidin complexes and developed with diaminobenzidine tetrahydrchloride (DAB) as substrate. Images of immunostained aortic root sections, captured digitally with a video camera connected to a Leica microscope, were analyzed using computerized image analysis (Image Pro Plus, Media Cybernetics, Silver Spring, MD). Total lesion area in aortic root sections was measured by manually tracing entire lesions in 8 equally spaced aortic root sections per mouse. Both macrophage and fibrous areas were quantified in sections by determination of area that stained positively for macrophage markers and laminin, respectively. The acquisition of images and analysis of lesions were performed in a blinded fashion.
Isoprostane analysis
For isoprostane measurement total lipids from urine, LDL and aortic homogenate samples were extracted with ice-cold Folch solution, chloroform/methanol (2:1, volume/volume) as described previously (19) . After removing aliquots for phospholipid measurement, the organic phase was dried under nitrogen. The samples were hydrolyzed by the addition of aqueous KOH (15%) and total iPF 2 α-VI was measured as described (19) .
Results
Effects of hepatic apoE expression on plasma lipids and lipoproteins
Mice that received Adnull had no significant change in plasma apoE levels during the course of the experiment, whereas mice that received AdhapoE3 had significantly increased plasma apoE levels, with the peak expression at day 7 (Fig.1A) . The plasma apoE levels in AdhapoE3-injected mice remained about two-fold higher than in Adnull mice 6 weeks after administration at the termination of the experiment. Despite the increase in plasma apoE levels, no significant changes in the plasma cholesterol levels from baseline were observed (Fig. 1B) . On day 7 after injection, the mean plasma cholesterol level in mice injected with AdhapoE3 (573 ± 48) were modestly lower than mice injected with Adnull (696 ± 61, p=NS), but there were no significant differences in cholesterol levels during the 6 weeks of the study. The mean post-injection cholesterol levels were not different between the two groups (AdhapoE3, 594 ± 18 vs Adnull, 663 ± 23, p=NS). Thus, hepatic expression of apoE had no significant effect on plasma cholesterol levels in LDLR-/-mice fed a western-type diet. Plasma triglyceride levels in mice injected with AdhapoE3 were transiently elevated at day 7 compared with control mice (data not shown) and did not differ at the remaining time points.
To evaluate the effect of hepatic apoE expression on plasma lipoproteins, pooled plasma samples drawn on day 7 were analyzed by FPLC gel filtration. This analysis showed no significant differences in the plasma lipoprotein profiles between Adnull control and AdhapoE3 mice (Fig. 1C ).
These results demonstrate that gene transfer and hepatic expression of apoE3 in LDLR-/-mice did not significantly alter the distribution of cholesterol among lipoprotein fractions. The distribution of human apoE3 was determined in the lipoprotein fractions and apoE was found to be primarily associated with VLDL and large HDL particles, with a smaller amount of apoE present on IDL and LDL fractions (data not shown). To determine whether lipoprotein composition was influenced, we isolated VLDL, LDL, and HDL by sequential ultracentrifugation from pooled plasma samples. Analysis of the lipoprotein cholesterol (free and esterified), phospholipid and protein composition revealed no significant differences in lipoprotein composition between Adnull and AdhapoE3 groups at days 7, 14, 28, or 42.
Effects of hepatic apoE expression on quantitative atherosclerosis
The extent of atherosclerosis was assessed by two independent methods: 1) en face quantitation of atherosclerosis in the aorta from just above the root to the renal arteries; 2) crosssectional analysis of atherosclerotic lesions in the aortic root. The Sudan-IV stained en face preparations of the LDLR-/-mouse aortas showed extensive atherosclerotic lesions throughout the entire aorta at baseline. The aortas from Adnull-injected control mice demonstrated further progression of atherosclerosis. In contrast, the lesions in AdhapoE3 mice were markedly reduced.
Quantitation of atherosclerosis using morphometric image analysis of the aortas demonstrated a marked 61% regression of atherosclerosis in mice injected with AdhapoE3 compared with baseline mice (Fig. 2A) . In LDLR-/-mice fed a western-type diet, atherosclerotic lesions develop initially in the proximal portions of the aorta, the aortic root and arch, and with progression of atherosclerosis, extend distally into thoracic and abdominal portions of the aorta. To assess the pattern of apoE-induced regression in different portions of the aorta, the lesion areas in the arch, thoracic and abdominal portions of the aorta were analyzed. The results show that hepatic apoE expression not only induced marked regression of advanced lesions in the thoracic and abdominal portions of the aorta, but also effectively regressed relatively more abundant lesions in the aortic arch (Fig. 2B) .
Atherosclerosis was also quantified in aortic root cross-sections by manually tracing the entire lesions in five equally-spaced sections from each mouse. Consistent with the en face data of the aorta, Adnull-injected mice showed progression of aortic root atherosclerotic lesions, whereas AdhapoE3-injected mice demonstrated significant 34% regression of lesion compared with baseline mice (Fig. 2C) . Thus, by two independent assays, hepatic expression of apoE induced significant regression of advanced atherosclerosis over a 6-week period.
Effects of hepatic apoE expression on morphology of atherosclerotic lesions
To evaluate the effects of liver-derived apoE on the morphology of lesions, we used immunocytochemistry to characterize their composition. Aortic root cross-sections from baseline, Adnull and AdhapoE3 mice were immunostained for macrophages with antibodies to β2-integrin (Mac-1, CD18, and CD11c) and for extracellular matrix-rich regions with an antibody to laminin. Lesions contained a large amount of non-macrophage foam cell components and laminin, consistent with advanced atherosclerotic lesions. Collagen staining was similar to laminin staining (data not shown).
Quantitative computer-assisted image analysis of immunostained aortic root serial cross-sections revealed significant reduction of macrophage-derived foam cells in atheroscleroic lesions of AdhapoE3 mice compared with baseline and Adnull mice (Fig. 3A) . In contrast, the distribution of laminin-rich areas showed no change (data not shown) and therefore the ratio of macrophage foam cells to laminin was significantly reduced in mice injected with AdhapoE3 (Fig. 3B) . These results show that liverderived apoE induced regression of preexisting advanced lesions primarily by reducing the macrophage-derived components of lesions but not the extracellular matrix components.
Analysis of human apoE in artery wall
In previous studies, we have shown that liver-derived apoE after gene transfer gained access to the artery wall and was specifically retained in areas of atherosclerotic lesions in apoE-/-mice (7). To demonstrate the retention of liver-derived human apoE in the artery wall in this study, aortic extracts prepared from baseline mice as well as Adnull and AdhapoE3 mice at the end of the experiment were analyzed by western blotting using monoclonal antibody specific for human apoE. The presence of liver-derived human apoE in the artery wall was detected in AdhapoE3 injected mice but not in Adnull and baseline mice (Fig. 4) . No human apoE mRNA was detected (data not shown), indicating that the human apoE present in the aorta was not synthesized within the vessel wall. Thus, liver-derived apoE gained access to the artery wall from the plasma compartment and was retained in substantial amounts within the artery wall several weeks after vector injection.
Effects of hepatic apoE expression on isoprostanes
To examine whether hepatic apoE expression affected in vivo oxidant stress, we measured iPF 2 α-VI levels in urine and plasma LDL before and at several time points after vector administration and in aorta at the termination of the experiment. Injection of Adnull had no effect on urinary iPF 2 α-VI levels; in contrast, hepatic expression of apoE significantly reduced urinary iPF 2 α-VI levels by 7 days and they remained at 60% of baseline values at 6 weeks (Fig. 5A) . Analysis of the LDL-associated iPF 2 α-VI levels showed no change in control mice, but a rapid reduction in the AdhapoE3-injected mice, with levels by 14 days only 6.3% of baseline values and remaining in that range through the 6 weeks of the experiment (Fig. 5B) . Finally, aortic iPF 2 α-VI levels in AdhapoE mice were significantly reduced compared with both baseline and Adnull mice (Fig. 5C ). These results suggest that hepatic apoE expression reduced oxidant stress in vivo. The apoE-mediated inhibition of lipid peroxidation and oxidative stress may contribute to its anti-atherogenic mechanisms in the regression of advanced atherosclerotic lesions.
Discussion
In this study, we demonstrated that hepatic overexpression of human apoE3 for 6 weeks induced regression of pre-existing advanced atherosclerosis in LDLR-deficient mice without reducing plasma cholesterol levels. This substantially extends our previous finding that apoE expression reduced the progression of early fatty streak lesions in LDLR-deficient mice (10) and indicates that liver-derived apoE has the potential to induce loss of foam cell mass from pre-existing advanced atherosclerotic lesions. Furthermore, we demonstrated that apoE overexpression in aged LDLRdeficient mice had markedly reduced levels of isoprostanes in urine, plasma, and aorta compared with baseline and control treated mice. We found that hepatic expression of apoE resulted in a profound reduction of urinary isoprostane excretion, LDL-associated isoprostanes, and vessel wall isoprostane content. These results strongly suggest that hepatic apoE expression resulted in anti-oxidant effects in vivo. Whether these effects were directly responsible for the induction of atherosclerosis regression remains to be determined.
It is not surprising that hepatic overexpression of human apoE3 on the background of endogenous mouse apoE and in the absence of the LDLR did not significantly reduce plasma cholesterol levels. The LDLR is the major physiologic receptor for apoE in the liver (23) and although there are backup mechanisms for clearance of lipoprotein remnants, such as LRP and HSPGs, they are much less efficient. Furthermore, the majority of plasma cholesterol in western-diet fed LDLR mouse is in LDL, which are generally not cleared from the plasma through an apoE-mediated mechanism. In fact, apoE-containing remnant lipoproteins can compete with LDL for uptake, resulting in delayed catabolism of LDL (24) . Furthermore, apoE has been shown to inhibit lipolysis of triglyceride-rich lipoproteins (25) . Finally, hepatic apoE expression enhances hepatic VLDL TG (26) (27) (28) and apoB production (29) . Therefore any modest effect of apoE in promoting clearance of VLDL in the absence of the LDLR may be offset by its effect in competing with LDL for clearance, inhibiting VLDL lipolysis, and promoting VLDL production. Our data demonstrate that apoE overexpression had a very modest effect in reducing VLDL cholesterol on day 7, but that this effect was no longer seen at subsequent time points. These data are consistent with studies that expressed apoE using bone marrow transplant (30) or by liver-directed gene transfer (25) in the absence of both apoE and the LDLR and found little effect on plasma cholesterol levels. Transgenic overexpression of apoE in the absence of the LDL receptor in mice demonstrated reduction in VLDL cholesterol and increased VLDL turnover but no reduction in LDL cholesterol or change in turnover (31) and transgenic overexpression of apoE in rabbits resulted in a 70% increase in plasma cholesterol due largely to increased LDL cholesterol (32) . Therefore, apoE expression has relatively little ability to reduce plasma cholesterol levels in the absence of the LDLR, making it a good animal model for assessing the direct effects of apoE expression on atherosclerosis and other markers without the confounding effects of a reduction in plasma cholesterol.
Macrophage-specific transgenic expression of apoE in apoE deficient mice reduced progression of atherosclerosis even after controlling for changes in plasma cholesterol levels (4).
Furthermore, when apoE-deficient bone marrow was transplanted into wild-type mice, atherosclerotic lesion formation was increased despite a lack of effect on plasma cholesterol levels (5). Thus, macrophage-derived apoE appears sufficient to inhibit the progression of atherosclerotic lesions independent of its effects on plasma lipoproteins. In a previous study, we demonstrated that liverderived apoE gained access to and accumulated within atherosclerotic lesions (7) . Therefore, it is likely that in these studies liver-derived apoE gained access to the vessel wall and had direct effects that promoted regression of lesions. Plasma apoE may gain access to the vessel wall in the context of small lipoprotein particles such as gamma-LpE (33,34) and preß-LpE (34) . Once within the intima, apoE could associate with components of the extracellular matrix, such as heparan sulfate proteoglycans (35, 36) and laminin (37), for which it has affinity.
There are a number of potential mechanisms by which hepatic apoE may have induced regression of atherosclerosis. ApoE promotes cellular cholesterol efflux (38) (39) (40) (41) (42) and is a contributor to the ability of plasma to induce cholesterol efflux from cells (43, 44) . However, apoE has been demonstrated in vitro to have other cellular effects such as inhibition of T-lymphocyte proliferation (17), inhibition of vascular smooth muscle cell proliferation (45) , and anti-oxidant effects (16) . However, the in vivo relevance of these observations has been uncertain. In these studies, we used quantitation of iPF 2 α-VI, a major isoprostane that is not influenced by cyclo-oxygenase activity and therefore felt to be a specific marker for lipid peroxidation and oxidant stress (18, 46) , to test the hypothesis that expression of apoE reduced oxidant stress in vivo. We found a dramatic effect of hepatic apoE expression in reducing urine, LDL-associated, and aortic levels of iPF 2 α-VI. This is the first in vivo evidence that apoE has direct anti-oxidant effects. Combined with our previous study in which vitamin E administration in apoE deficient mice reduced isoprostane generation accompanied by reduction in atherosclerosis (19) , this finding further supports the concept that isoprostanes may be a surrogate marker for anti-oxidant effects of interventions which are likely to beneficially influence atherosclerosis.
The findings in our studies advance the concept of apoE as an anti-atherogenic molecule in several important ways. First, we expressed apoE in the liver instead of macrophages, demonstrating that apoE is anti-atherogenic regardless of whether it is presented to the vessel wall via macrophages or via the plasma compartment. This suggests that interventions to raise hepatic production and plasma levels of apoE could be anti-atherogenic even if macrophage production of apoE is not increased. Second, we demonstrated that apoE induced regression of pre-existing advanced atherosclerotic lesions, which has not been previously demonstrated for apoE derived from any source.
Inhibition of progression and induction of regression involve very different cellular and molecular processes (47) and the difference between these two processes is of potential clinical significance.
Third, we demonstrated that apoE changed the morphology of advanced lesions-reduced foam cells and increased matrix--in a way that could be interpreted as consistent with "stabilization" of lesions (48) . Finally, we showed that hepatic apoE expression markedly reduced isoprostanes, an accepted index of in vivo oxidant stress, providing important evidence that the in vitro anti-oxidant properties of apoE that were previously described are also functional in vivo and suggesting another mechanism by which apoE may be anti-atherogenic.
In summary, we demonstrate that liver-directed gene transfer and hepatic expression of apoE in LDLR-/-mice induced significant regression of advanced atherosclerotic lesions without substantial alteration in plasma cholesterol and lipoprotein levels. In addition, apoE expression markedly reduced isoprostane levels in urine, plasma LDL and aortic tissue. These results demonstrate that liver-derived apoE has direct anti-atherogenic and antioxidant properties in vivo that are independent of cholesterol and lipoprotein modulation. Lipoprotein cholesterol distribution. Pooled Day-7 plasma samples from 9 LDLR-/-mice each from Adnull (triangles) and AdhapoE3 (squares) group were subjected to FPLC gel filtration using two Superose 6 columns. Cholesterol levels of the fractions obtained were determined by an enzymatic assay. 5) and AdhapoE (lanes 6 and 7) mice were loaded on the gel at two concentrations (10 µg aortic protein, lanes 2,4 and 6, and 15 µg aortic protein, lanes 3, 5 and 7). The 34 kd bands corresponding to human apoE are detectable in the aorta from AdhapoE mice 6 weeks after viral injection. This band is absent in aortas from Baseline and Adnull mice. by guest on July 16, 2017 
